GlobeNewswire Inc.··Rosen Law FirmUltragenyx Faces Securities Lawsuit Over Misleading Clinical Trial Claims
Securities class action filed against RARE over alleged false statements regarding Phase III clinical trials for setrusumab. Claim deadline April 6, 2026.
RAREinvestor lossessecurities class action